Objective:To study the effect of lncRNA CTD-2510F5.4 silencing on the proliferation and invasion of huh-7 human hepatocellular carcinoma cells and its possible regulatory relationship with RACGAP1.Methods:The TCGA(The...Objective:To study the effect of lncRNA CTD-2510F5.4 silencing on the proliferation and invasion of huh-7 human hepatocellular carcinoma cells and its possible regulatory relationship with RACGAP1.Methods:The TCGA(The Cancer Genome Atlas)database was used to analyze the expression of lncRNA CTD-2510F5.4 in liver cancer and normal tissues and the correlation with the expression of RACGAP1.CTD-2510F5.4 silencing test was performed on Huh-7 human liver cancer cells,and PCR was used to verify its silencing efficiency.CCK8,Transwell,flow cytometry were used to detect cell proliferation,invasion,and apoptosis,RTPCR,and Western blot.Detect the expression level of RACGAP1.Results:In the TCGA database,lncRNA CTD-2510F5.4 was highly expressed in liver cancer tissues,and it was positively correlated with the expression of RACGAP1(R=0.85).After silencing CTD-2510F5.4,the proliferation and invasion of huh-7 human liver cancer cells were inhibited,apoptosis increased,and the mRNA and protein expression of RACGAP1 were downregulated.Conclusion:lncRNA CTD-2510F5.4 may be the oncogenic lncRNA of liver cancer,and RACGAP1 may be the target of lncRNA CTD-2510F5.4.Silencing CTD-2510F5.4 can inhibit the proliferation and invasion of huh-7 human liver cancer cells,and promote apoptosis,which may be achieved by inhibiting the expression of RACGAP1.展开更多
Objective:To explore the expression and clinical significance of RACGAP1 gene in hepatocellular carcinoma.Methods:Data about RACGAP1 gene and clinic pathological data in liver cancer were retrieved from The Cancer Gen...Objective:To explore the expression and clinical significance of RACGAP1 gene in hepatocellular carcinoma.Methods:Data about RACGAP1 gene and clinic pathological data in liver cancer were retrieved from The Cancer Genome Atlas(TCGA).The relationship between the expression of RACGAP1 gene and clinic pathological parameters,and prognosis were analyzed by R 2.15.3 software.The association between RACGAP1 gene expression and prognosis of liver cancer patients was analyzed by Kaplan-Meier survival function analysis and Cox regression analysis.Results:TCGA database was used to collect 235 cases of liver cancer with clinical pathological parameters and their corresponding RACGAP1 expression levels.After the incomplete cases and those with no detailed pathological parameters were excluded,and it was found that RACGAP1 was highly expressed in liver cancer tissues.Meanwhile,the expression of RACGAP1 in patients with liver cancer in the TCGA tumor database was further analyzed with the matching clinical data parameters.The expression level of RACGAP1 was significantly correlated with the pathological grade and T stage of liver cancer patients(all P<0.05),but was not significantly correlated with American Joint Committee on Cancer(AJCC)pathological stage and gender(P>0.05).There was a significant correlation between RACGAP1 expression level and overall survival(OS)in patients with liver cancer(P<0.05),and the overall survival time of patients with low expression was better than that of patients with high expression(P<0.05).Cox regression was used to analyze the correlation between T stage,M stage,N stage and RACGAP1 expression in patients with hepatocellular carcinoma(HCC),and RACGAP1 became an independent prognostic factor in patients with HCC(P<0.05).Conclusion:Based on the tumor-related gene information in the public database TCGA,RACGAP1 gene is highly expressed in liver cancer tissues and becomes an independent prognostic factor of liver cancer,which is expected to become an important therapeutic target of drug therapy for liver cancer.展开更多
基金Baise City Scientific Research and Technology Development Plan(No.20195405)。
文摘Objective:To study the effect of lncRNA CTD-2510F5.4 silencing on the proliferation and invasion of huh-7 human hepatocellular carcinoma cells and its possible regulatory relationship with RACGAP1.Methods:The TCGA(The Cancer Genome Atlas)database was used to analyze the expression of lncRNA CTD-2510F5.4 in liver cancer and normal tissues and the correlation with the expression of RACGAP1.CTD-2510F5.4 silencing test was performed on Huh-7 human liver cancer cells,and PCR was used to verify its silencing efficiency.CCK8,Transwell,flow cytometry were used to detect cell proliferation,invasion,and apoptosis,RTPCR,and Western blot.Detect the expression level of RACGAP1.Results:In the TCGA database,lncRNA CTD-2510F5.4 was highly expressed in liver cancer tissues,and it was positively correlated with the expression of RACGAP1(R=0.85).After silencing CTD-2510F5.4,the proliferation and invasion of huh-7 human liver cancer cells were inhibited,apoptosis increased,and the mRNA and protein expression of RACGAP1 were downregulated.Conclusion:lncRNA CTD-2510F5.4 may be the oncogenic lncRNA of liver cancer,and RACGAP1 may be the target of lncRNA CTD-2510F5.4.Silencing CTD-2510F5.4 can inhibit the proliferation and invasion of huh-7 human liver cancer cells,and promote apoptosis,which may be achieved by inhibiting the expression of RACGAP1.
文摘Objective:To explore the expression and clinical significance of RACGAP1 gene in hepatocellular carcinoma.Methods:Data about RACGAP1 gene and clinic pathological data in liver cancer were retrieved from The Cancer Genome Atlas(TCGA).The relationship between the expression of RACGAP1 gene and clinic pathological parameters,and prognosis were analyzed by R 2.15.3 software.The association between RACGAP1 gene expression and prognosis of liver cancer patients was analyzed by Kaplan-Meier survival function analysis and Cox regression analysis.Results:TCGA database was used to collect 235 cases of liver cancer with clinical pathological parameters and their corresponding RACGAP1 expression levels.After the incomplete cases and those with no detailed pathological parameters were excluded,and it was found that RACGAP1 was highly expressed in liver cancer tissues.Meanwhile,the expression of RACGAP1 in patients with liver cancer in the TCGA tumor database was further analyzed with the matching clinical data parameters.The expression level of RACGAP1 was significantly correlated with the pathological grade and T stage of liver cancer patients(all P<0.05),but was not significantly correlated with American Joint Committee on Cancer(AJCC)pathological stage and gender(P>0.05).There was a significant correlation between RACGAP1 expression level and overall survival(OS)in patients with liver cancer(P<0.05),and the overall survival time of patients with low expression was better than that of patients with high expression(P<0.05).Cox regression was used to analyze the correlation between T stage,M stage,N stage and RACGAP1 expression in patients with hepatocellular carcinoma(HCC),and RACGAP1 became an independent prognostic factor in patients with HCC(P<0.05).Conclusion:Based on the tumor-related gene information in the public database TCGA,RACGAP1 gene is highly expressed in liver cancer tissues and becomes an independent prognostic factor of liver cancer,which is expected to become an important therapeutic target of drug therapy for liver cancer.
